Medtronic’s Symplicity Spyral RDN System Approved in China

May 6, 2024—Medtronic announced it received approval from the National Medical Products Administration (NMPA) in China for its Symplicity Spyral renal denervation (RDN) system.

Endovascular Engineering Helo Thrombectomy System for Acute PE Evaluated in ENGULF Trial

May 3, 2024—Late-breaking data from the ENGULF trial showed that the dual-action Helo pulmonary embolism (PE) thrombectomy system (Endovascular Engineering [E2]) was effective and safe in treating acute PE.

APEX-AV Trial Evaluates AngioDynamics’ AlphaVac F18⁸⁵ Mechanical Thrombectomy System to Treat PE

May 3, 2024—The safety and efficacy results from the APEX-AV trial of acute pulmonary embolism (PE) extraction with the AlphaVac F1885 aspiration system (AngioDynamics, Inc.) demonstrated that catheter-directed mechanical thrombectomy is safe and effective in patients with acute intermediate-risk PE with significant improvement in the right ventricle (RV) function and minimal major adverse events.

Outcomes of PCI Before, During, or After TAVR With Edwards’ Sapien 3 Platform Analyzed in TVT Registry Data

May 3, 2024—An analysis including 49,344 patients with stable coronary artery disease (CAD) showed that percutaneous coronary intervention (PCI) can be safely performed before, during, or after transcatheter aortic valve replacement (TAVR) in these patients.

Data From REAL-PE Analysis Show Disparities in Catheter-Based PE Treatment

May 3, 2024—New data from the REAL-PE analysis, which investigated catheter-based pulmonary embolism (PE) treatment, showed that women and Black patients were less frequently treated with minimally invasive therapy compared to men or non-Black patients.

Anteris’ DurAVR Biomimetic TAVR Device Studied to Treat Symptomatic AS Patients

May 3, 2024—The safety and feasibility of the biomimetic DurAVR transcatheter heart valve system (Anteris Technologies) in the treatment of patients with severe symptomatic aortic stenosis (AS) were evaluated in a prospective nonrandomized, single-arm, single-center, first-in-human (FIH) study of 28 patients.

SMART Analysis Compares Hemodynamic Performance of Self-Expanding and Balloon-Expandable TAVR Devices

May 3, 2024—An analysis from the SMART trial demonstrated clinical noninferiority of self-expanding versus balloon-expandable valves in patients with aortic stenosis (AS) and small aortic annuli (SAA) undergoing transcatheter aortic valve replacement (TAVR).

Studies Find Underrepresented Groups Remain at Highest Risk of Heart Attack Despite 50% National Incidence Decline

May 3, 2024—Two studies focusing on ST‐segment elevation myocardial infarction (STEMI) uncovered socioeconomic, race, and gender disparities that are associated with greater risk and less likelihood to receive certain procedures.

TAVR and SAVR Compared to Treat Patients With Aortic Stenosis and Cardiogenic Shock

May 2, 2024—A nationwide observational analysis of patients with aortic stenosis (AS) and cardiogenic shock (CS) who underwent transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) determined that patients who underwent TAVR had lower in-hospital complications and resource utilization compared with SAVR.

CALORI Trial Explores Nonfasting Preprocedural Strategy for Cardiac Catheterization

May 2, 2024—The CALORI Cardiac Catheterization trial, which focuses on inpatients undergoing elective or urgent cardiac catheterization procedures, is a single-center, randomized trial investigating the impact of fasting after midnight versus unrestricted oral intake prior to cardiac catheterization.